



# CEE UPDATES

## December 2024

### SHARING THE IMPACT OF SINGAPORE'S PATIENT INVOLVEMENT ACTIVITIES


#### European Society for Medical Oncology (ESMO) Patient Engagement Summit, 8 December 2024, Singapore

The first ESMO Patient Engagement Summit 'Advancing Cancer Care in Asia-Pacific' was launched during the ESMO Asia Congress 2024. At the summit, the CEE team highlighted the successful collaborative efforts between ACE and local patient organisations to include the patient voice in health technology assessments (HTAs) which inform funding decisions for cancer treatments. The summit highlighted best practice examples of patient engagement from Asia and Europe, and served as a valuable platform for patient representatives, healthcare professionals, and industry representatives to identify regional opportunities and challenges to shape impactful health policies to advance cancer care.



#### HTAi-HTAsiaLink webinar: Patient and Citizen Involvement in HTA across the Asia-Pacific Region, 21 November 2024

At the first joint webinar between HTAi and HTAsiaLink, Ms Fiona Pearce, ACE's Senior Adviser and Co-Chair of the HTAi Patient and Citizen Involvement Interest Group (PCIG) discussed the importance of meaningful patient involvement in HTA. Representatives from HTA agencies and patient organisations across the Asia Pacific region, including Candy Gan from typeOne.sg in Singapore, also shared their experiences involving patients' voices in healthcare decision-making and highlighted aspirations for future engagement opportunities.



Click [here](#) to access the recording of the webinar

# STRENGTHENING PARTNERSHIPS AND AMPLIFYING PATIENT VOICES IN HTA

## ACE Consumer Panel meeting, 2 December 2024



The CEE team held a hybrid meeting with the ACE Consumer Panel to celebrate the success of new patient involvement initiatives implemented in 2024 and to discuss CEE's future strategic direction. We thank the Panel for their important insights and active participation this year and look forward to continuing our strong collaboration to advance patient involvement in HTA in Singapore in 2025. Find out more about the ACE Consumer Panel [here](#).

## Highlight videos from ACE Value-Based Healthcare Conference patient-centred breakout session

The CEE team has produced three highlight videos from our breakout session "Co-creating Meaningful Patient Engagement in Healthcare", which was held on 23 August 2024 during the ACE Conference. Click [here](#) to hear directly from the participants as they explain why patients are essential partners in healthcare decision-making, and how we can all work towards transforming patient engagement in Singapore!



## ANNUAL CALL FOR TOPICS IS CLOSING SOON



The **annual call for topics** is now open for patients, carers and patient organisations to suggest which drugs or medical devices ACE should evaluate for different health conditions.

Click [here](#) to read our factsheet which describes the key steps of the application process.

Topic suggestions should be submitted by **31 January 2025**. Contact the CEE team or your patient organisation for an application form.

NEW

# HTA LEARNING MODULE FOR PATIENTS AND CARERS



The CEE team has co-developed a new learning module with the ACE Consumer Panel on ***“What is health technology assessment (HTA)?”***

This module provides an introduction to health technologies and HTA and includes a simple self-assessment quiz.

Click [here](#) to download the module. Stay tuned for more learning modules next year!

FIND OUT MORE

NEW

# PATIENT EDUCATION AIDS


FIND OUT MORE

## 2 PATIENT EDUCATION AIDS WERE PUBLISHED IN NOVEMBER 2024

Patient education aids are co-developed with patient organisations and clinicians to support the implementation of ACE Clinical Guidances by providing patients with basic and helpful information about different health conditions, treatments, medical tests and tips for better self-management.

### New patient education aids:

- Bronchodilator inhalers for chronic obstructive pulmonary disease (COPD)
- Spirometry for lung conditions




We would like to thank members from the patient organisations who provided feedback and suggestions to help inform the content and layout of these new patient education aids.

## 1 PATIENT FACTSHEET UPDATED SINCE NOVEMBER 2024

FIND OUT MORE

- Hormone therapy for advanced prostate cancer (updated)



## PLAIN ENGLISH SUMMARIES

## 8 NEW PLAIN ENGLISH SUMMARIES PUBLISHED SINCE SEPTEMBER 2024

FIND OUT MORE

Plain English summaries (PES) provide brief information about the treatments and conditions that have been evaluated by ACE and describe the key funding recommendations made by the MOH advisory committees.

### Newly published PES:

- Axicabtagene ciloleucel for treating relapsed or refractory large B-cell lymphoma
- Cabotegravir with rilpivirine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection
- Dostarlimab for treating primary advanced or recurrent endometrial cancer
- Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19
- Recombinant zoster vaccine for preventing shingles and related nerve pain
- Selexipag for treating pulmonary arterial hypertension
- Trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer (updated)
- Treatments for advanced prostate cancer (updated)





# 46

## PATIENT RESPONSES WERE GATHERED FOR TOPICS PRESENTED TO THE MOH ADVISORY COMMITTEES IN NOVEMBER 2024



The effort put in by patients to share their experiences is appreciated and every input is valuable to ACE and MOH. The CEE team notifies patient organisations of the advisory committees' funding recommendations after each meeting and provides feedback on which information provided by patients was most helpful to inform the committees' deliberations. The CEE team also invites suggestions on how the patient involvement processes can be improved through this [link](#).

# Season's Greetings



*The CEE team would like to thank the ACE Consumer Panel and all local patient organisations for their contributions and support in 2024. We look forward to continuing working with you next year to elevate the patient voice in healthcare decision-making.*

*We wish everyone a joyous holiday season, and a happy and healthy new year!*

### About CEE

The Consumer Engagement and Education (CEE) team supports patient involvement in ACE's work and co-develops plain English summaries and educational resources with patient organisations to improve health literacy and encourage shared healthcare decision-making between patients and their doctors.

Tell us what matters to you, your organisation or your community. Email us at [ACE\\_CEE@moh.gov.sg](mailto:ACE_CEE@moh.gov.sg).



The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance and education. © Agency for Care Effectiveness, Ministry of Health, Republic of Singapore.

Published on 23 December 2024. To find out more about ACE, scan the QR code or visit [www.ace-hta.gov.sg](http://www.ace-hta.gov.sg). You can also follow us on social media at: 